VU
Valence8 US Portfolio holdings
AUM
$238M
This Quarter Return
+5.83%
1 Year Return
+14.65%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$229M
AUM Growth
+$229M
(+20%)
Cap. Flow
+$26.2M
Cap. Flow
% of AUM
11.43%
Top 10 Holdings %
Top 10 Hldgs %
96.09%
Holding
56
New
31
Increased
3
Reduced
4
Closed
–
Top Buys
| 1 |
iShares MSCI USA Quality Factor ETF
QUAL
|
$6.53M |
| 2 |
Invesco QQQ Trust
QQQ
|
$5.58M |
| 3 |
iShares MSCI Intl Quality Factor ETF
IQLT
|
$5.56M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$999K |
| 5 |
Bristol-Myers Squibb
BMY
|
$920K |
Top Sells
| 1 |
Vanguard Value ETF
VTV
|
$589K |
| 2 |
Utilities Select Sector SPDR Fund
XLU
|
$295K |
| 3 |
iShares MSCI United Kingdom ETF
EWU
|
$284K |
| 4 |
Consumers Staples Select Sector SPDR Fund
XLP
|
$252K |
Sector Composition
| 1 | Healthcare | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Gossamer Bio
GOSS
$562M
| – | – | 0 | – | – |
|
52
Iovance Biotherapeutics
IOVA
$807M
| – | – | 0 | – | – |
|
53
Moderna
MRNA
$9.37B
| – | – | 0 | – | – |
|
54
Novo Nordisk
NVO
$251B
| – | – | 0 | – | – |
|
55
Cassava Sciences
SAVA
$110M
| – | – | 0 | – | – |
|
56
Viridian Therapeutics
VRDN
$1.5B
| – | – | 0 | – | – |
|